FDA

Latest News

luchschenF-stock@adobe.com
FDA Extends Review of Blenrep Combinations in Multiple Myeloma

July 24th 2025

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.

Timon-stock-adobe.com
Sarepta to Pause Shipments of the Gene Therapy Elevidys

July 22nd 2025

Timon-stock.abode.com
FDA Wants Elevidys Off the Market. Sarepta Said No.

July 19th 2025

FDA Approves Ekterly, First Oral Treatment for Hereditary Angioedema
FDA Approves Ekterly, First Oral Treatment for Hereditary Angioedema

July 7th 2025

FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma
FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma

June 19th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.